This phase II, open-label, single-arm trial was designed to prospectively estimate the efficacy of panitumumab plus FOLFIRI treatment as a function of tumor KRAS status in patients undergoing second-line treatment for metastatic CRC. Here, KRAS is linked to colorectal carcinoma.